Meyka Pro banner
ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc. (NASDAQ: CLPT) Stock Competitors & Peer Comparison

See CLPT's competitors and their performance on the NASDAQ and across the wider stock market.

CLPTNASDAQ
HealthcareMedical - Devices
$15.42
$0.24(1.58%)
U.S. Market opens in 3h 56m

Peer Comparison Table: Medical - Devices Industry

Detailed financial metrics including price, market cap, P/E ratio, and more for CLPT and its NASDAQ peers.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
CLPT$14.21+6.12%426.2M-12.04-$1.18N/A
ABT$107.81-0.14%186.5B20.69$5.21+2.31%
BSX-PA$122.18+2.37%175.4B230.53$0.53N/A
SYK$339.03+0.47%130B25.32$13.39+1.03%
MDT$87.16+1.44%111.6B15.76$5.53+3.29%
BSX$49.31+0.02%73.3B15.91$3.10N/A
EW$89.72+0.45%51.7B33.23$2.70N/A
DXCM$84.75+2.08%32B36.37$2.33N/A
RMD$211.94-5.06%30.7B19.68$10.77+1.15%
PHG$26.73+1.52%26.1B15.28$1.75+3.70%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

Abbott Laboratories (NYSE: ABT)

CLPT vs ABT Comparison August 2026

ClearPoint Neuro, Inc. (NASDAQ: CLPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CLPT stands at 426.2M. In comparison, ABT has a market cap of 186.5B. Regarding current trading prices, CLPT is priced at $14.21 on the NASDAQ, while ABT trades at $107.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CLPT currently has a P/E ratio of -12.04, whereas ABT's P/E ratio is 20.69. In terms of profitability, CLPT's ROE is -1.88%, compared to ABT's ROE of +0.11%. Regarding short-term risk, CLPT is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for CLPT.Check ABT's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions